Nanoscope Therapeutics is developing optogenetic gene therapies using Multi-Characteristic Opsin (MCO) to re-sensitize the retina to detect low light levels. These therapies have the potential to restore vision in millions of visually impaired individuals suffering from retinal degenerative diseases, including Retinitis Pigmentosa, Stargardt Disease and Dry Age-related Macular Degeneration (AMD).

MCO-010 for RP and Stargardt Disease

Our lead product, MCO-010, is in clinical development for retinitis pigmentosa (RP) and Stargardt disease, which are two rare retinal diseases that cause blindness. MCO-010 has been granted Orphan Drug designation by the US Food and Drug Administration for both diseases.

MCOs have potential to address all forms of retinal degeneration and are applicable for patients suffering from complete or partial damage to the retina.

Nanoscope’s MCO-010 gene therapy utilizes a convenient and well-established intraocular injection for delivery of a gene that encodes for the ambient light-sensitive MCO protein into retinal cells.  These therapies are intended to enable  retinal cells to detect light  so that patients with retinitis pigmentosa or Stargardt disease may see again.

How our proprietary technology differs from other gene therapies

Our therapy focuses on treating blindness regardless of the underlying genetic mutation

It is an ambient-light sensitive therapy in which a polychromatic Opsin is delivered to retinal cells enabling vision in different color environments

Simple and convenient office-based procedure, invasive ocular surgery not required

No external device or stimulation is required, eliminating risk of photo-toxicity

Nano-enhanced Optical Delivery – NOD

Imagine delivering new genetic material to retinal cells with no viruses at all.  The company has strategic partnerships to create a unique non-viral alternative gene delivery platform designed to improve targeting precision with less immunogenicity. The non-viral technology involves a near-infrared laser-based spatially targeted nano-enhanced delivery (NOD) of therapeutic genes. This technology can be used to deliver competent genes to correct the underlying genetic defects that lead to vision loss, as well as optical gene therapies.

Nanoscope Therapeutics, Inc.
1312 Brown Trail, Suite A
Bedford, TX 76022
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) has decades of Biomedical Technologies experience  in Asia, Europe and USA.  He has authored over 200 publications and patents.  He is the Primary Investigator for major grants from National Eye Institute including  Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award.